enVVeno Medical Management
Management criteria checks 2/4
enVVeno Medical's CEO is Robert Berman, appointed in Apr 2018, has a tenure of 6.58 years. total yearly compensation is $1.87M, comprised of 26.7% salary and 73.3% bonuses, including company stock and options. directly owns 0.058% of the company’s shares, worth $34.49K. The average tenure of the management team and the board of directors is 5.5 years and 6.1 years respectively.
Key information
Robert Berman
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 26.7% |
| CEO tenure | 6.6yrs |
| CEO ownership | 0.06% |
| Management average tenure | 5.5yrs |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation
Jun 26
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
Mar 07Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?
Aug 14Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?
Apr 22We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate
Dec 21enVVeno Medical: Unique Exposure To Venous Treatment Domain
Sep 23We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely
Aug 23enVVeno Medical reports Q2 results
Aug 03We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth
May 10We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate
Jan 25Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics
Sep 08Hancock Jaffe Laboratories finance chief sheds interim tag
Dec 31Hancock Jaffe approves 1:25 reverse stock split
Nov 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$21m |
| Jun 30 2024 | n/a | n/a | -US$21m |
| Mar 31 2024 | n/a | n/a | -US$22m |
| Dec 31 2023 | US$2m | US$500k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | n/a | n/a | -US$25m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$466k | US$450k | -US$25m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$24m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$10m | US$400k | -US$17m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$1m | US$400k | -US$10m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$7m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$415k | US$400k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$7m |
| Jun 30 2019 | n/a | n/a | -US$7m |
| Mar 31 2019 | n/a | n/a | -US$13m |
| Dec 31 2018 | US$906k | US$293k | -US$16m |
Compensation vs Market: Robert's total compensation ($USD1.87M) is above average for companies of similar size in the US market ($USD653.78K).
Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.
CEO
Robert Berman (61 yo)
6.6yrs
Tenure
US$1,870,884
Compensation
Mr. Robert A. Berman serves as Chief Executive Officer and Director of enVVeno Medical Corporation (formerly known as Hancock Jaffe Laboratories, Inc.) since April 2018. From September 2017 to March 2018,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.6yrs | US$1.87m | 0.058% $ 34.5k | |
| CFO, Treasurer & Secretary | 4.6yrs | US$527.29k | 0% $ 0 | |
| Senior VP & Chief Technology Officer | 1.8yrs | US$669.19k | no data | |
| Senior VP & Chief Medical Officer | 8.5yrs | US$776.38k | 0.0091% $ 5.4k | |
| Co-founder | 37.8yrs | no data | no data | |
| Vice President of Marketing | less than a year | no data | no data | |
| Chief Medical Officer of Outside of United States | 6.5yrs | US$240.00k | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
5.5yrs
Average Tenure
65yo
Average Age
Experienced Management: NVNO's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.6yrs | US$1.87m | 0.058% $ 34.5k | |
| Independent Director | 5.2yrs | US$77.50k | 0.044% $ 25.8k | |
| Independent Director | 5.2yrs | US$75.00k | 0.039% $ 23.3k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 6.1yrs | US$70.00k | 0.12% $ 70.5k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 6.1yrs | US$75.00k | 0.022% $ 13.1k |
6.1yrs
Average Tenure
62yo
Average Age
Experienced Board: NVNO's board of directors are considered experienced (6.1 years average tenure).